MX2012010343A - Administracion transdermica de peptidos. - Google Patents
Administracion transdermica de peptidos.Info
- Publication number
- MX2012010343A MX2012010343A MX2012010343A MX2012010343A MX2012010343A MX 2012010343 A MX2012010343 A MX 2012010343A MX 2012010343 A MX2012010343 A MX 2012010343A MX 2012010343 A MX2012010343 A MX 2012010343A MX 2012010343 A MX2012010343 A MX 2012010343A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- peptides
- transdermal administration
- fatty acid
- salts
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000035699 permeability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20100174A IE20100174A1 (en) | 2010-03-25 | 2010-03-25 | Transdermal administration of peptides |
| PCT/IE2011/000019 WO2011117851A1 (en) | 2010-03-25 | 2011-03-23 | Transdermal administration of peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012010343A true MX2012010343A (es) | 2013-01-29 |
Family
ID=44210069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010343A MX2012010343A (es) | 2010-03-25 | 2011-03-23 | Administracion transdermica de peptidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130085105A1 (OSRAM) |
| EP (1) | EP2550005A1 (OSRAM) |
| JP (1) | JP2013523629A (OSRAM) |
| KR (1) | KR20130062275A (OSRAM) |
| CN (1) | CN102883735A (OSRAM) |
| AU (1) | AU2011231173A1 (OSRAM) |
| BR (1) | BR112012022377A2 (OSRAM) |
| CA (1) | CA2792470A1 (OSRAM) |
| IE (1) | IE20100174A1 (OSRAM) |
| MX (1) | MX2012010343A (OSRAM) |
| RU (1) | RU2012145278A (OSRAM) |
| WO (1) | WO2011117851A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5486690B2 (ja) | 2009-11-16 | 2014-05-07 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンドの医薬組成物 |
| MX343499B (es) * | 2010-03-15 | 2016-11-08 | Ipsen Pharma Sas | Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. |
| EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
| JP5965909B2 (ja) | 2010-09-28 | 2016-08-10 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9295637B2 (en) * | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| EP2979702A4 (en) * | 2013-03-25 | 2016-11-16 | Zeria Pharm Co Ltd | GASTROKINETIC POSTPRANDIAL MEDIUM |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3166967T3 (pl) * | 2014-09-14 | 2023-07-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Syntetyczne ligandy receptora somatostatyny |
| CA2984357A1 (en) | 2015-04-29 | 2016-11-03 | Radius Pharmaceuticals, Inc. | Methods for treating cancer |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| CA3027563C (en) | 2016-06-22 | 2024-07-02 | Ellipses Pharma Ltd | AR+ METHODS FOR BREAST CANCER TREATMENT |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| KR101786914B1 (ko) * | 2017-01-31 | 2017-11-15 | 주식회사 삼양사 | 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드 |
| CN107226840A (zh) * | 2017-05-04 | 2017-10-03 | 西安交通大学 | 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用 |
| EP3687508A1 (en) * | 2017-09-26 | 2020-08-05 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
| US11969460B2 (en) * | 2018-06-08 | 2024-04-30 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
| IL279853B2 (en) | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
| IT201800009384A1 (it) * | 2018-10-11 | 2020-04-11 | Cosmo Srl | Peptide for cosmetic application |
| CN119390714A (zh) | 2019-02-12 | 2025-02-07 | 雷迪厄斯制药公司 | 方法和化合物 |
| DE102020130492A1 (de) * | 2020-11-18 | 2022-05-19 | Lts Lohmann Therapie-Systeme Ag. | Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle |
| WO2023281447A1 (en) * | 2021-07-07 | 2023-01-12 | Radius Health, Inc. | Methods of treating a cardiovascular ischemic event |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954975A (en) * | 1972-02-17 | 1976-05-04 | Ciba-Geigy Corporation | Salts of ACTH-peptides and processes for their manufacture |
| IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
| EP0671937A4 (en) * | 1992-10-16 | 1996-09-18 | Smithkline Beecham Corp | COMPOSITIONS FOR PHARMACEUTICAL EMULSIONS. |
| US6316414B1 (en) * | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| CA2450446A1 (en) * | 2001-06-25 | 2003-01-03 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| US20030175329A1 (en) * | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| WO2006040447A1 (fr) * | 2004-10-07 | 2006-04-20 | L'oreal | Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase |
| US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
| AU2007233116B2 (en) * | 2006-03-30 | 2013-05-09 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| WO2008008363A1 (en) * | 2006-07-11 | 2008-01-17 | Qps, Llc | Pharmaceutical compositions for sustained release delivery of peptides |
| GB0705264D0 (en) * | 2007-03-20 | 2007-04-25 | Pliva Istrazivanje I Razvoj D | Gel forming compounds |
| US20100196264A1 (en) * | 2007-05-18 | 2010-08-05 | The Brigham And Women's Hospital, Inc. | Use of somatostatin analogs in myocardial perfusion imaging |
| WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
-
2010
- 2010-03-25 IE IE20100174A patent/IE20100174A1/en not_active IP Right Cessation
-
2011
- 2011-03-23 JP JP2013500647A patent/JP2013523629A/ja not_active Ceased
- 2011-03-23 RU RU2012145278/15A patent/RU2012145278A/ru not_active Application Discontinuation
- 2011-03-23 BR BR112012022377A patent/BR112012022377A2/pt not_active IP Right Cessation
- 2011-03-23 EP EP11712680A patent/EP2550005A1/en not_active Withdrawn
- 2011-03-23 MX MX2012010343A patent/MX2012010343A/es not_active Application Discontinuation
- 2011-03-23 CN CN2011800157799A patent/CN102883735A/zh active Pending
- 2011-03-23 AU AU2011231173A patent/AU2011231173A1/en not_active Abandoned
- 2011-03-23 CA CA2792470A patent/CA2792470A1/en not_active Abandoned
- 2011-03-23 KR KR1020127027694A patent/KR20130062275A/ko not_active Withdrawn
- 2011-03-23 WO PCT/IE2011/000019 patent/WO2011117851A1/en not_active Ceased
- 2011-03-23 US US13/637,244 patent/US20130085105A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012022377A2 (pt) | 2017-01-10 |
| CN102883735A (zh) | 2013-01-16 |
| JP2013523629A (ja) | 2013-06-17 |
| RU2012145278A (ru) | 2014-04-27 |
| KR20130062275A (ko) | 2013-06-12 |
| WO2011117851A1 (en) | 2011-09-29 |
| EP2550005A1 (en) | 2013-01-30 |
| AU2011231173A1 (en) | 2012-10-18 |
| CA2792470A1 (en) | 2011-09-29 |
| IE20100174A1 (en) | 2012-02-29 |
| US20130085105A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012010343A (es) | Administracion transdermica de peptidos. | |
| CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
| JOP20180103A1 (ar) | مركب صيدلاني | |
| CY1115595T1 (el) | Αλατα ρασιγιλινης και φαρμακευτικη παρασκευη αυτων | |
| MY156274A (en) | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | |
| MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
| EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
| UA111142C2 (uk) | Одержання заміщених похідних 2-фторакрилової кислоти | |
| BR112014028334A2 (pt) | derivados dipeptídicos de lisina ácido glutâmico. | |
| ZA201305786B (en) | Improved production of protein solutions from soy | |
| MX348831B (es) | Administración parenteral de tapentadol. | |
| PH12014502856A1 (en) | Solid pharmaceutical preparation containing levothyroxine | |
| EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| EP3677261B8 (en) | Administration of serine protease inhibitors to the stomach | |
| EA201300733A1 (ru) | Рекомбинантные микобактерии в качестве вакцины | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| UA106386C2 (ru) | Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой | |
| MD4615B1 (ro) | Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine | |
| IN2014DN09451A (OSRAM) | ||
| FR2981089B1 (fr) | Production d'isopropanol par des souches recombinantes ameliorees | |
| IN2014MN01376A (OSRAM) | ||
| BR112012027753A2 (pt) | preparação de polipeptídeos e sais dos mesmos | |
| WO2013046233A3 (en) | Process for the preparation of octreotide acetate | |
| TR201009166A2 (tr) | Sefdinir içeren farmasötik bileşim için üretim yöntemi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |